the prospect of big change at the regulatory agency comes as drugmakers are under fire for high prices including marathon pharmaceuticals llc which said monday it was pausing the launch of its duchenne muscular dystrophy drug after u s lawmakers questioned its dollar quatre-vingt-neuf virgule zéro zéro a year price